LUMO lumos-pharma.com Net earnings per share for the last 12 months

Public company logo of Lumos Pharma, Inc. (LUMO)

Lumos Pharma, Inc. (LUMO) profit potential relies on insurance reimbursements for comfortable therapy for patients with growth hormone deficiency. Stable demand for medical innovations gives the asset defensive qualities, as illustrated by the net income per share over the last 12 months, where the -4.26 level represents the current value. This confirms the biopharma company's success in developing oral stimulants that replace painful injections.

LUMO (Lumos Therapeutics) Net earnings per share (EPS TTM) history from 07/04/2022 to 12/21/2024

Analytical breakdowns and data insights for company Lumos Therapeutics (LUMO)

- stock price and consensus target price:
Fundamental company valuation:Lumos Pharma Inc (LUMO)
Mass-produced product of Lumos Pharma Corp

To filter market risks, Lumos Pharma, Inc. (LUMO) must decouple price volatility from actual returns. This indicator is calculated as the ratio of total annual net income to the number of shares outstanding. By analyzing changes in the rolling net income per share, an investor can observe the actual business efficiency without emotional distortions. Growth in this metric confirms financial stability. The localization of research in the US and the humanitarian status of the drugs minimize external threats to this indicator.

Competitors of Lumos Pharma, Inc.

Ascendis - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Madrigal Pharma|CORT (Corcept Therapeutics Incorporated) - Net earnings per share for the last 12 months|RYTM: Earnings per share for the last four quarters|AKRO (Akero Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Metsera Inc|Net earnings per share (EPS TTM) MLTX|Earnings per share for the last twelve months CRNX (Crinetics Pharmaceuticals, Inc.)|Earnings per share for the last twelve months newamsterdampharma.com NAMS|Soleno Therapeutics Corp (SLNO) - Net earnings per one share for the last twelve months|FOLD - Earnings per share for the last twelve months|ETNB: Earnings per share for the last twelve months|AGIO: Net earnings per share (EPS TTM)|GPCR - Net earnings per share for the last four quarters|Earnings per share for the last twelve months MiMedx Corp|Rezolute Bio (RZLT) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months lexpharma.com (LXRX)|Net earnings per share for the last 12 months MBX Biosciences Inc MBX|Earnings per share for the last twelve months Altimmune ALT|Net earnings per share (EPS TTM) Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BioAge Labs, Inc BIOA|Biomea Fusion Inc (BMEA) - Earnings per share for the last twelve months|QNCX - Net earnings per share for the last four quarters|GUTS (Fractyl Health Inc.) - Net earnings per share (EPS TTM)|VTVT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATPC|Net earnings per share for the last four quarters Pluri Inc|Net earnings per share (EPS TTM) SYBX (Synlogic Corp)|Net earnings per share for the last four quarters lipocine.com (LPCN)|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months ONVO|Net earnings per one share for the last twelve months Radius Recycling, Inc. RDUS